Skip to content
MarketScale
‹ Back to IndustriesHealthcare

CurveBeam Unveils New Logo

On the heels of a recent FDA approval for its LineUP system, CurveBeam unveiled a fresh, new look as it poises itself to enjoy a remarkable leadership position in the healthcare industry. CurveBeam unveiled a new logo design that it will transition to using in all branded content and materials. “CurveBeam’s primary focus is innovation,”…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

On the heels of a recent FDA approval for its LineUP system, CurveBeam unveiled a fresh, new look as it poises itself to enjoy a remarkable leadership position in the healthcare industry.

CurveBeam unveiled a new logo design that it will transition to using in all branded content and materials.

“CurveBeam’s primary focus is innovation,” explains Marketing Manager Vinti Singh. “Our new logo incorporates subtle design updates that reflect our culture of constant adaptation and change. However, the color scheme and swoop motif are preserved as a symbol of a commitment to our core values.”

With a line of cone beam scanning devices, CurveBeam allows clinics to offer weight bearing CT scanning to their patients to improve their quality of care. Here is the latest overview of the CurveBeam product line:

  • The InReach update this link is an extremity cone beam CT scanner that images the hand, wrist, forearm, elbow and the lower extremities. The InReach is the most compact orthopedic extremity CT scanner available.
  • The LineUP provides bilateral, weight-bearing CT imaging of the knee and lower extremities to redefine orthopedic care.
  • The pedCAT update this link is a compact, ultra-low dose CT imaging system that is ideal for orthopedic and podiatric clinics. Patients benefit from the convenience of point-of-care advanced diagnostic imaging. Scan time is one minute, and the pedCAT automatically generates all standard X-Ray views in addition to the full CT volume.
  • CubeVue software provides powerful visualization tools to enhance diagnosis. The pedCAT system comes complete with CubeVue installed. CubeVue automatically generates all standard X-Ray views, possibly eliminating the need for your plain X-Ray system altogether. Insta-X views are free from magnification, distortion or patient positioning inaccuracies.

CurveBeam has refreshed its brand and is committed to staying at the forefront of the orthopedic field as the healthcare industry evolves. As its team continues to push forward with new technology, CurveBeam is continuously evolving, always innovating, and keeping its approach to product development fresh.

CurveBeam was founded in 2009 by a group of individuals with a proven track record in the advanced and compact 3D imaging device domain. Learn more about the exciting things happening at CurveBeam today by our blog.

Read more at curvebeam.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus has made a $450 million deal with Alkeus to acquire two assets, including a phase 3 oral Stargardt program and a post-injection antiseptic. The focus now moves to clinical trial operations, chemistry manufacturing and controls, and plans for specialty distribution. These acquisitions aim to expand Tarsus' retina programs.

  • 01Tarsus acquired a phase 3 oral Stargardt asset and a post-injection antiseptic for $450 million.
  • 02The acquisitions focus on enhancing clinical trial operations and chemistry manufacturing controls.
  • 03Plans for future specialty distribution of the acquired assets are in place.

Aug 29, 2026

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

The FDA has released a generative AI discussion paper proposing a shift towards competency-style evaluation and increased postmarket monitoring in the healthcare industry. This move may lead vendors and hospital buyers to prioritize developing robust testing protocols for AI applications. The focus is on ensuring reliable and safe AI implementation in medical technologies.

  • 01The FDA's discussion paper suggests implementing competency-style evaluation for AI in healthcare.
  • 02There is an emphasis on increased postmarket monitoring for AI applications in the medical field.
  • 03Vendors and hospital buyers are encouraged to focus on developing testing protocols rather than presentations.

Aug 29, 2026

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 is focusing on integrating smart glasses and AI into the purchasing processes for optical retailers and labs. The event is anticipated to attract around 34,000 visitors and feature 950 exhibitors, indicating significant interest in AI imaging workflows and smart-glass innovations. The agenda highlights a future direction towards advanced technology in optical retail and laboratory settings.

  • 01SILMO Paris 2026 will host nearly 34,000 visitors and 950 exhibitors.
  • 02The event focuses on AI imaging workflows and smart-glass innovations for optical retailers and labs.
  • 03Significant interest is shown in integrating advanced technology within optical retail processes.

Aug 29, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512